{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(1)"],"submitter":["Ramirez-Fort MK"],"pubmed_abstract":["Folate Hydrolase-1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo-vasculature. Monoclonal antibody (mAb), J591, is a vehicle for mAb-based brachytherapy in FOLH1+ cancers. Brachytherapy is a form of radiotherapy that involves placing a radioactive material a short distance from the target tissue (e.g., on the skin or internally); brachytherapy is commonly accomplished with the use of catheters, needles, metal seeds and antibody or small peptide conjugates. Herein, FOLH1 expression in primary (p) and metastatic (m) Merkel cell carcinoma (MCC) is characterized to determine its targeting potential for J591-brachytherapy. Paraffin sections from pMCC and mMCC were evaluated by immunohistochemistry for FOLH1. Monte Carlo simulation was performed using t"],"journal":["Skin health and disease"],"pagination":["e9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8447486"],"repository":["biostudies-literature"],"pubmed_title":["Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma."],"pmcid":["PMC8447486"],"pubmed_authors":["Liu H","Sheng Y","Niaz MJ","Navarro V","Nghiem PT","Lachance K","Nguyen DP","Bander NH","Ramirez-Fort MK","Meier-Schiesser B","French LE","Hadravsky L","Tagawa ST","Nikolopoulou A","Mahase SS","Sach J","Kazakov DV","Contassot E","Church CD","Lange CS","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma.","description":"Folate Hydrolase-1 (FOLH1; PSMA) is a type II transmembrane protein, luminally expressed by solid tumour neo-vasculature. Monoclonal antibody (mAb), J591, is a vehicle for mAb-based brachytherapy in FOLH1+ cancers. Brachytherapy is a form of radiotherapy that involves placing a radioactive material a short distance from the target tissue (e.g., on the skin or internally); brachytherapy is commonly accomplished with the use of catheters, needles, metal seeds and antibody or small peptide conjugates. Herein, FOLH1 expression in primary (p) and metastatic (m) Merkel cell carcinoma (MCC) is characterized to determine its targeting potential for J591-brachytherapy. Paraffin sections from pMCC and mMCC were evaluated by immunohistochemistry for FOLH1. Monte Carlo simulation was performed using t","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-19T13:43:17.087Z","creation":"2024-12-04T03:37:42.809Z"},"accession":"S-EPMC8447486","cross_references":{"pubmed":["34541577"],"doi":["10.1002/ski2.9"]}}